317 related articles for article (PubMed ID: 30488763)
1. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Fisher RP
Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibitors as anticancer drugs.
Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
4. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
[TBL] [Abstract][Full Text] [Related]
5. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II.
Glover-Cutter K; Larochelle S; Erickson B; Zhang C; Shokat K; Fisher RP; Bentley DL
Mol Cell Biol; 2009 Oct; 29(20):5455-64. PubMed ID: 19667075
[TBL] [Abstract][Full Text] [Related]
6. Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications.
Ebmeier CC; Erickson B; Allen BL; Allen MA; Kim H; Fong N; Jacobsen JR; Liang K; Shilatifard A; Dowell RD; Old WM; Bentley DL; Taatjes DJ
Cell Rep; 2017 Aug; 20(5):1173-1186. PubMed ID: 28768201
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Liang H; Du J; Elhassan RM; Hou X; Fang H
Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
[No Abstract] [Full Text] [Related]
8. The CDK Network: Linking Cycles of Cell Division and Gene Expression.
Fisher RP
Genes Cancer; 2012 Nov; 3(11-12):731-8. PubMed ID: 23634260
[TBL] [Abstract][Full Text] [Related]
9. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?
Lolli G; Johnson LN
Cell Cycle; 2005 Apr; 4(4):572-7. PubMed ID: 15876871
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription.
Rimel JK; Poss ZC; Erickson B; Maas ZL; Ebmeier CC; Johnson JL; Decker TM; Yaron TM; Bradley MJ; Hamman KB; Hu S; Malojcic G; Marineau JJ; White PW; Brault M; Tao L; DeRoy P; Clavette C; Nayak S; Damon LJ; Kaltheuner IH; Bunch H; Cantley LC; Geyer M; Iwasa J; Dowell RD; Bentley DL; Old WM; Taatjes DJ
Genes Dev; 2020 Nov; 34(21-22):1452-1473. PubMed ID: 33060135
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for CDK7 activation by MAT1 and Cyclin H.
Peissert S; Schlosser A; Kendel R; Kuper J; Kisker C
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26739-26748. PubMed ID: 33055219
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase inhibitor p16INK4A inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH.
Serizawa H
J Biol Chem; 1998 Mar; 273(10):5427-30. PubMed ID: 9488660
[TBL] [Abstract][Full Text] [Related]
14. cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos.
Wallenfang MR; Seydoux G
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5527-32. PubMed ID: 11960010
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of transcriptional cyclin-dependent kinases.
Galbraith MD; Bender H; Espinosa JM
Transcription; 2019 Apr; 10(2):118-136. PubMed ID: 30409083
[TBL] [Abstract][Full Text] [Related]
16. The cryoelectron microscopy structure of the human CDK-activating kinase.
Greber BJ; Perez-Bertoldi JM; Lim K; Iavarone AT; Toso DB; Nogales E
Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22849-22857. PubMed ID: 32855301
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CDK7 substrate specificity by MAT1 and TFIIH.
Yankulov KY; Bentley DL
EMBO J; 1997 Apr; 16(7):1638-46. PubMed ID: 9130709
[TBL] [Abstract][Full Text] [Related]
18. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
20. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Diab S; Yu M; Wang S
J Med Chem; 2020 Jul; 63(14):7458-7474. PubMed ID: 32150405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
